Literature DB >> 3667878

The ontogeny of serum GH binding protein in man: a possible indicator of hepatic GH receptor development.

W H Daughaday1, B Trivedi, B A Andrews.   

Abstract

Experiments in rabbits suggest that a serum GH binding protein (GH-BP) probably is derived largely from hepatic membrane bound GH receptors. Human serum contains a specific GH binding protein which can be easily measured by incubation with [125I] hGH and separation of [125I] hGH-BP complexes from free [125I] hGH by gel filtration through an Ultrogel AcA 44 minicolumn. In each assay GH-BP activity of a reference (normal young adult) serum is similarly run and the results are expressed as a percentage of the activity of the unknown serum divided by the GH-BP activity of the reference serum after correction for the expected inhibition of GH binding resulting from the GH content of the unknown serum. The mean relative specific GH binding protein (RSGH-BP) of cord serum from 11 premature infants was only 3.2 +/- 1.4% (SE) and of cord serum from 17 full term infants was 14.9 +/- 2.5%. During the first two decades of life there was a progressive rise of RSGH-BP with considerable individual variation. The mean serum RSGH-BP of 13 such subjects was 54.5 +/- 6.2%. More uniform RSGH-BP results were obtained in serum from 15 young adults, 91.7 +/- 7.4%. Lower RSGH-BP 77.2 +/- 5.4% was found in serum from 12 healthy older adults (age 60 to 70 years). The low levels of RSGH-BP in fetal serum are consistent with the reported low concentrations of GH receptors in sheep and rat fetal liver membranes. We suggest the measurement of GH-BP activity provides a simple, noninvasive measure of the ontogeny of GH receptors of human beings.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3667878     DOI: 10.1210/jcem-65-5-1072

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  8 in total

Review 1.  Medical management of growth hormone-secreting pituitary adenomas.

Authors:  Michael S Racine; Ariel L Barkan
Journal:  Pituitary       Date:  2002       Impact factor: 4.107

Review 2.  Circulating growth hormone binding proteins.

Authors:  G Baumann; M A Shaw; K Amburn
Journal:  J Endocrinol Invest       Date:  1994-01       Impact factor: 4.256

3.  Growth hormone secretion in children and adolescents with familial tall stature.

Authors:  M Tauber; C Pienkowski; P Rochiccioli
Journal:  Eur J Pediatr       Date:  1994-05       Impact factor: 3.183

4.  Serum growth hormone-binding protein is decreased in prepubertal children with idiopathic short stature.

Authors:  N Dávila; M Moreira-Andrés; J Alcañiz; B Barceló
Journal:  J Endocrinol Invest       Date:  1996-06       Impact factor: 4.256

Review 5.  Somatostatin analogs in medical treatment of acromegaly.

Authors:  Michael S Racine; Ariel L Barkan
Journal:  Endocrine       Date:  2003-04       Impact factor: 3.633

6.  Serum levels of growth hormone-binding protein and insulin-like growth factor I in children and adolescents with type 1 (insulin-dependent) diabetes mellitus.

Authors:  G Massa; L Dooms; R Bouillon; M Vanderschueren-Lodeweyckx
Journal:  Diabetologia       Date:  1993-03       Impact factor: 10.122

7.  Influence of the high-affinity growth hormone (GH)-binding protein on plasma profiles of free and bound GH and on the apparent half-life of GH. Modeling analysis and clinical applications.

Authors:  J D Veldhuis; M L Johnson; L M Faunt; M Mercado; G Baumann
Journal:  J Clin Invest       Date:  1993-02       Impact factor: 14.808

Review 8.  Involvement of brain catecholamines and acetylcholine in growth hormone hypersecretory states. Pathophysiological, diagnostic and therapeutic implications.

Authors:  E E Müller; M Rolla; E Ghigo; D Belliti; E Arvat; A Andreoni; A Torsello; V Locatelli; F Camanni
Journal:  Drugs       Date:  1995-11       Impact factor: 9.546

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.